Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus Inc. CEO Garo H. Armen received 3,349 shares of common stock at $4.87 per share in lieu of cash salary for the pay period ending October 4, 2024, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Agenus Inc.'s CEO, Garo H. Armen, received 3,349 shares of common stock on October 4, 2024, as payment for his salary.
• The stock was issued at a price of $4.87 per share, which was the closing price of Agenus Inc. common stock on that date.
• This arrangement was made at Dr. Armen's request and with the approval of the Agenus Inc. Compensation Committee.
• The shares were issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
• Dr. Armen also indirectly owns 31,298 shares through IRA accounts and 28,950 shares as trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT and as a general partner in Pixie Partners.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The fact that the CEO is taking stock instead of cash could be interpreted as a positive sign of confidence, but it could also be a sign that the company is trying to conserve cash.

Positives

• The CEO accepting stock in lieu of cash salary could be seen as a positive signal, indicating confidence in the company's future performance.
• The stock was issued under the 2019 Equity Incentive plan, aligning the CEO's interests with those of shareholders.

Industry Context

In the biotech industry, it is not uncommon for executives to receive stock options or grants as part of their compensation packages. This aligns their interests with the long-term success of the company. The CEO taking stock in lieu of salary is a more aggressive move.

Comparison to Industry Standards

• Comparing this to industry standards, companies like Amgen and Gilead Sciences often use a mix of salary, stock options, and performance-based bonuses for executive compensation.
• The specific allocation varies based on company size, stage of development, and individual performance.
• For example, the CEO of a similar-sized biotech company, such as BioNTech, might have a compensation package that includes a base salary, stock options vesting over several years, and performance-based bonuses tied to clinical trial milestones or product approvals.

Stakeholder Impact

• Shareholders may view the CEO's decision to take stock in lieu of cash salary as a positive sign of confidence in the company's future.
• Employees may see this as a sign that the company is managing its cash resources carefully.

Key Dates